Minerva Neurosciences (NERV) Change in Accured Expenses (2013 - 2026)

Minerva Neurosciences (NERV) has 14 years of Change in Accured Expenses data on file, last reported at $796544.0 in Q1 2026.

• Quarterly Change in Accured Expenses rose 918.3% year-over-year to $796544.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (up 1276.95% YoY) and the FY2025 annual result came in at $317446.0, up 203.71% from the prior year.
• Change in Accured Expenses improved to $796544.0 in Q1 2026, from -$145868.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.0 million in Q2 2024 to a low of -$2.7 million in Q4 2024.
• A 5-year average of $81014.8 and a median of $78223.0 in 2025 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 2773.82% in 2024, down 543.84% in 2024.
• Tracing NERV's Change in Accured Expenses over 5 years: stood at -$1.3 million in 2022, then soared by 66.6% to -$419493.0 in 2023, then sank by 543.84% to -$2.7 million in 2024, then jumped by 94.6% to -$145868.0 in 2025, then soared by 646.07% to $796544.0 in 2026.
• The last three Change in Accured Expenses figures came in at $796544.0 (Q1 2026), -$145868.0 (Q4 2025), and $60255.0 (Q3 2025), per Business Quant data.